[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 849,240
  • Shares Outstanding, K 30,330
  • Annual Sales, $ 344,230 K
  • Annual Income, $ -24,160 K
  • EBIT $ -25 M
  • EBITDA $ 12 M
  • 60-Month Beta 1.00
  • Price/Sales 2.36
  • Price/Cash Flow 24.07
  • Price/Book 1.76

Options Overview Details

View History
  • Implied Volatility 73.86% (-7.18%)
  • Historical Volatility 46.58%
  • IV Percentile 59%
  • IV Rank 52.05%
  • IV High 101.74% on 02/20/26
  • IV Low 43.60% on 08/19/25
  • Expected Move (DTE 19) 5.27 (18.82%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 232
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 139
  • Open Int (30-Day) 257
  • Expected Range 22.73 to 33.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 1
  • High Estimate $-0.33
  • Low Estimate $-0.33
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) -1,550.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.46 +24.67%
on 07/13/26
30.81 -9.12%
on 07/31/26
+4.15 (+17.40%)
since 06/30/26
3-Month
17.72 +58.00%
on 05/14/26
30.81 -9.12%
on 07/31/26
+3.51 (+14.33%)
since 04/30/26
52-Week
14.59 +91.91%
on 08/04/25
44.28 -36.77%
on 01/26/26
+11.92 (+74.13%)
since 07/30/25

Most Recent Stories

More News
Castle Biosciences Reports Second Quarter 2026 Results

Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% ...

CSTL : 28.00 (+4.52%)
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference

FRIENDSWOOD, Texas , July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 28.00 (+4.52%)
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis

CSTL : 28.00 (+4.52%)
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

FRIENDSWOOD, Texas , July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 28.00 (+4.52%)
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma...

CSTL : 28.00 (+4.52%)
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Stokes was one of 22 financial leaders recognized in the Greater Houston area

CSTL : 28.00 (+4.52%)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRIENDSWOOD, Texas , June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June...

CSTL : 28.00 (+4.52%)
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

FRIENDSWOOD, Texas , June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 28.00 (+4.52%)
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas , May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 28.00 (+4.52%)
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions

CSTL : 28.00 (+4.52%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 33.35
2nd Resistance Point 32.08
1st Resistance Point 30.04
Last Price 28.00
1st Support Level 26.73
2nd Support Level 25.46
3rd Support Level 23.42

See More

52-Week High 44.28
Fibonacci 61.8% 32.94
Fibonacci 50% 29.43
Last Price 28.00
Fibonacci 38.2% 25.93
52-Week Low 14.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.